Herantis Pharma Plc HRTIS

Herantis Pharma Plc – Press release Indivi’s digital biomarker platform is designed to enable earlier and more sensitive detection of treatment-related changes Improved sensitivity and reduced variability may support more efficient clinical studies, including shorter study duration and smaller patient cohorts Espoo, Finland, May 19, 2026: Herantis Pharma Plc ("Herantis"), a clinical-stage company developing disease-modifying therapies to stop the progression of Parkinson’s disease, announces a c

Espoo, Finland, March 16, 2026: Herantis Pharma Plc ("Herantis"), a clinical-stage company developing disease-modifying therapies to stop the progression of Parkinson’s disease, announces that its Chief Scientific Officer, Henri Huttunen, will be delivering an oral presentation at the 20th International Conference on Alzheimer’s & Parkinson’s Diseases and Related Neurological Disorders (AD/PD 2026), held in Denmark from 17-21 March, on data from Herantis’s Phase 1b trial of HER-096 in people liv

Herantis Pharma Plc – Company release Inside information: Herantis Pharma – Phase 1b biomarker data show clear evidence of biological response to HER-096 in people with Parkinson's disease Biomarker data show that HER-096 modulates Parkinson’s disease-relevant pathways, consistent with preclinical data, and supporting further clinical developmentHER-096 exposure was associated with changes across key disease-related pathways, including proteostasis, mitochondrial function, and neuroinflammation,